Worth Venture Partners LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,469 shares of the company’s stock, valued at approximately $702,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NBIX. Janus Henderson Group PLC purchased a new position in Neurocrine Biosciences during the 2nd quarter worth $246,888,000. BlackRock Inc. increased its holdings in Neurocrine Biosciences by 14,216.0% during the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the period. TimesSquare Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 299.4% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock valued at $106,507,000 after acquiring an additional 1,735,700 shares during the period. HealthCor Management L.P. increased its holdings in shares of Neurocrine Biosciences by 108.2% in the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock valued at $117,308,000 after acquiring an additional 1,325,178 shares during the period. Finally, FMR LLC increased its holdings in shares of Neurocrine Biosciences by 9.8% in the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after acquiring an additional 1,180,874 shares during the period.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded down $0.82 during trading on Tuesday, hitting $74.64. The stock had a trading volume of 603,900 shares, compared to its average volume of 1,128,458. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same period in the prior year, the firm posted ($0.43) EPS. equities research analysts expect that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/11/14/worth-venture-partners-llc-invests-702000-in-neurocrine-biosciences-inc-nbix-stock.html.
NBIX has been the topic of a number of analyst reports. Robert W. Baird reiterated an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Leerink Swann reiterated an “outperform” rating and issued a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Cowen and Company reiterated an “outperform” rating and issued a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Finally, Barclays PLC lifted their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average target price of $78.88.
In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the completion of the sale, the insider now owns 101,790 shares of the company’s stock, valued at approximately $5,852,925. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 140,810 shares of company stock valued at $9,035,398. 4.80% of the stock is currently owned by insiders.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.